304 related articles for article (PubMed ID: 31295667)
1. Primary central nervous system lymphoma: Novel precision therapies.
Mondello P; Mian M; Bertoni F
Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
[TBL] [Abstract][Full Text] [Related]
2. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Illerhaus G; Schorb E; Kasenda B
Blood; 2018 Aug; 132(7):681-688. PubMed ID: 29986908
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Zhang Y; Zhou DB
Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
6. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
7. [New treatment strategies for primary lymphoma of the central nervous system].
Seidel S; Kaulen L; von Baumgarten L
Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
[TBL] [Abstract][Full Text] [Related]
8. Recent developments and controversies in primary central nervous system lymphoma.
Hottinger AF; Alentorn A; Hoang-Xuan K
Curr Opin Oncol; 2015 Nov; 27(6):496-501. PubMed ID: 26371780
[TBL] [Abstract][Full Text] [Related]
9. Central Nervous System Lymphoma.
Chukwueke UN; Nayak L
Hematol Oncol Clin North Am; 2019 Aug; 33(4):597-611. PubMed ID: 31229157
[TBL] [Abstract][Full Text] [Related]
10. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
[TBL] [Abstract][Full Text] [Related]
12. The possible role of maintenance treatment for primary central nervous system lymphoma.
Bairey O; Siegal T
Blood Rev; 2018 Sep; 32(5):378-386. PubMed ID: 29551465
[TBL] [Abstract][Full Text] [Related]
13. Evolving Treatments for Primary Central Nervous System Lymphoma.
Ferreri AJM; Holdhoff M; Nayak L; Rubenstein JL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():454-466. PubMed ID: 31099614
[TBL] [Abstract][Full Text] [Related]
14. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
[No Abstract] [Full Text] [Related]
15. [Recent advances in the treatment of primary central nervous system lymphoma].
Nakamaki T
Brain Nerve; 2014 Aug; 66(8):969-79. PubMed ID: 25082318
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Grommes C; Rubenstein JL; DeAngelis LM; Ferreri AJM; Batchelor TT
Neuro Oncol; 2019 Feb; 21(3):296-305. PubMed ID: 30418592
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
18. Current management of primary central nervous system lymphoma.
Glass J
Chin Clin Oncol; 2017 Aug; 6(4):38. PubMed ID: 28841800
[TBL] [Abstract][Full Text] [Related]
19. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
20. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
Hayano A; Takashima Y; Yamanaka R
Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]